Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIS 703802 in Hypertriglyceridemia, T2DM, and NAFLD
NCT03371355Phase 2Completed
- Sponsor
- Akcea Therapeutics
- Start
- Dec 2017
- Primary completion
- Nov 2019
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 2
01
Overview
A Phase 2 trial of vupanorsen in hypertriglyceridemia, type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), sponsored by Akcea Therapeutics. Started Dec 2017; status: completed.
02
Drugs
vupanorsen
03
Conditions
hypertriglyceridemiatype 2 diabetes mellitus (T2DM)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT03371355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03371355.